Enzymotec Ltd. (NASDAQ:ENZY) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday, October 17th.
According to Zacks, “Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. “
Separately, ValuEngine upgraded Enzymotec from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Four investment analysts have rated the stock with a hold rating, Enzymotec currently has an average rating of “Hold” and an average price target of $11.75.
Shares of Enzymotec (NASDAQ ENZY) traded down $0.03 during mid-day trading on Tuesday, hitting $11.78. The stock had a trading volume of 179,127 shares, compared to its average volume of 272,997. Enzymotec has a twelve month low of $5.20 and a twelve month high of $12.35.
Enzymotec (NASDAQ:ENZY) last posted its quarterly earnings data on Wednesday, August 16th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.15). The company had revenue of $13.00 million for the quarter, compared to analysts’ expectations of $12.78 million. Enzymotec had a negative return on equity of 3.88% and a negative net margin of 14.52%. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.04 EPS. sell-side analysts forecast that Enzymotec will post 0.01 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Enzymotec Ltd. (ENZY) Stock Rating Upgraded by Zacks Investment Research” was originally posted by BBNS and is owned by of BBNS. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://baseballnewssource.com/markets/enzymotec-ltd-enzy-lifted-to-hold-at-zacks-investment-research/1720918.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp lifted its stake in shares of Enzymotec by 1.8% in the 2nd quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock valued at $169,000 after purchasing an additional 380 shares in the last quarter. Osborn Williams & Donohoe LLC acquired a new position in shares of Enzymotec in the 3rd quarter valued at about $137,000. Finally, Janus Henderson Group PLC acquired a new position in shares of Enzymotec in the 2nd quarter valued at about $2,350,000. 26.46% of the stock is currently owned by institutional investors and hedge funds.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with our FREE daily email newsletter.